CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,791,880 | +220.3% | 262,000 | +94.1% | 4.06% | +120.7% |
| Q2 2023 | $2,432,700 | +51.5% | 135,000 | +35.0% | 1.84% | +106.6% |
| Q1 2023 | $1,606,000 | -64.1% | 100,000 | -51.0% | 0.89% | -40.6% |
| Q1 2022 | $4,478,000 | -52.4% | 204,000 | -38.4% | 1.50% | -42.2% |
| Q4 2021 | $9,404,000 | +131.5% | 331,000 | +71.5% | 2.59% | +143.2% |
| Q3 2021 | $4,063,000 | -59.6% | 193,000 | -63.8% | 1.07% | -54.3% |
| Q2 2021 | $10,048,000 | +81.7% | 533,033 | +47.3% | 2.33% | +51.9% |
| Q1 2021 | $5,530,000 | +8.3% | 361,930 | 0.0% | 1.54% | -19.5% |
| Q4 2020 | $5,107,000 | – | 361,930 | – | 1.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 820,720 | $17,276,000 | 7.15% |
| 5AM Venture Management, LLC | 1,362,286 | $28,676,000 | 5.82% |
| Bain Capital Life Sciences Investors, LLC | 1,679,701 | $35,358,000 | 2.19% |
| Opaleye Management Inc. | 402,113 | $8,464,000 | 1.58% |
| FRAZIER MANAGEMENT LLC | 851,306 | $17,920,000 | 1.43% |
| Perceptive Advisors | 3,963,517 | $83,432,000 | 1.21% |
| Altium Capital Management LP | 193,000 | $4,063,000 | 1.07% |
| MPM BioImpact LLC | 298,392 | $6,281,000 | 0.97% |
| SPHERA FUNDS MANAGEMENT LTD. | 548,643 | $11,549,000 | 0.97% |
| Ghost Tree Capital, LLC | 150,000 | $3,158,000 | 0.92% |